Enara Bio
London
About Enara Bio
Enara Bio is a science-led company targeting the T-cell/cancer cell interface (the “immune synapse”) to develop new targeted cancer immunotherapies designed to treat a broad patient population. Enara Bio focuses on discovering and developing therapeutic cancer vaccines utilizing novel antigens derived from endogenous retroviral (ERV)-related DNA sequences.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $50.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Oct 2024)
- Website: enarabio.com
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/enara-bio-30201 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.